IMRN vs. RNXT, RDHL, AGE, COCP, AYTU, SYBX, NNVC, FBIO, VBIV, and JAN
Should you be buying Immuron stock or one of its competitors? The main competitors of Immuron include RenovoRx (RNXT), RedHill Biopharma (RDHL), AgeX Therapeutics (AGE), Cocrystal Pharma (COCP), Aytu BioPharma (AYTU), Synlogic (SYBX), NanoViricides (NNVC), Fortress Biotech (FBIO), VBI Vaccines (VBIV), and JanOne (JAN). These companies are all part of the "pharmaceutical preparations" industry.
Immuron (NASDAQ:IMRN) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, community ranking, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.
In the previous week, Immuron had 2 more articles in the media than RenovoRx. MarketBeat recorded 4 mentions for Immuron and 2 mentions for RenovoRx. RenovoRx's average media sentiment score of 0.44 beat Immuron's score of 0.00 indicating that RenovoRx is being referred to more favorably in the news media.
Immuron has higher revenue and earnings than RenovoRx.
Immuron received 181 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 67.75% of users gave Immuron an outperform vote while only 37.50% of users gave RenovoRx an outperform vote.
Immuron's return on equity of 0.00% beat RenovoRx's return on equity.
RenovoRx has a consensus target price of $8.50, suggesting a potential upside of 534.33%. Given RenovoRx's higher possible upside, analysts clearly believe RenovoRx is more favorable than Immuron.
Immuron has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, RenovoRx has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.
0.1% of Immuron shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 7.0% of Immuron shares are held by insiders. Comparatively, 9.0% of RenovoRx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Immuron beats RenovoRx on 8 of the 13 factors compared between the two stocks.
Get Immuron News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools